Veradermics Completes Enrollment in Second Phase 3 Trial of VDPHL01 for Hair Loss
Veradermics, a subsidiary of Mane, has completed enrollment in its second pivotal Phase 3 trial of VDPHL01 targeting male pattern hair loss across multiple international sites. This milestone advances VDPHL01 toward a regulatory filing, with topline efficacy and safety data expected by year-end.
1. Enrollment Milestone
Veradermics has finalized enrollment in its second pivotal Phase 3 trial of VDPHL01 for male pattern hair loss, securing participation across multiple international sites. The double-blind, randomized, placebo-controlled study will assess both safety and efficacy throughout the treatment period.
2. Next Development Steps
With enrollment now closed, Veradermics will proceed to data analysis and expects to report topline efficacy and safety results by year-end. Positive outcomes would pave the way for a Biologics License Application submission in 2027 and support VDPHL01’s commercial launch strategy.